Newsletter mensile Aiom
Anno V – Numero 49, Novembre 2022
Comitato scientifico editoriale: Vanna Chiarion Sileni, Paola Queirolo
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini
 
Notizie dalla ricerca

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy. To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy …
Continua a leggere


 

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma. We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously every 4 weeks) …
Continua a leggere


 

Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition

We aimed to investigate sex-related differences in patients with advanced melanoma treated with ICI by linking the assessment of inflammatory response in peripheral blood, onset of immune-related adverse events IRAEs during therapy and treatment response in short- and long-term. For the purpose of this single-center retrospective study metastatic melanoma patients treated with ICI were included. Baseline patient characteristics …
Continua a leggere


 

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Patients with stage IIB or IIC melanoma who undergo surgery alone are at a substantial risk for disease recurrence. Adjuvant pembrolizumab significantly improved recurrence-free survival versus placebo in stage IIB or IIC melanoma in the first interim analysis of the KEYNOTE-716 trial. Here, we report results from the secondary endpoint of distant metastasis-free survival (prespecified third interim analysis), and recurrence-free survival with longer follow-up …
Continua a leggere


 

Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma

The approval of ipilimumab (anti–cytotoxic T-cell lymphocyte [CTLA]4 Ab) in 2011 initiated the era of modern immunotherapy in cancer and has subsequently led to a dramatic improvement in outcomes for patients with melanoma. With the eventual success of other checkpoint blocking antibodies against programmed cell death protein 1 (PD-1; nivolumab and pembrolizumab) and more recently LAG3 (relatlimab), combination immune checkpoint blockade has become a standard for most patients. …
Continua a leggere


 

Appuntamenti Aiom


Avviso a tutti i Soci

A causa del protrarsi dell’emergenza coronavirus e delle relative disposizioni, si suggerisce di verificare la conferma dei singoli eventi direttamente con gli organizzatori

Comunicare il cancro, la medicina e la salute
FAD, giugno – dicembre 2022

I Farmaci Coniugati: un focus sullo stato dell’arte
Roma, 11 novembre 2022

Corso – Integrazione Ospedale Territorio
Cremona, 12 – 13 / 26 – 27 novembre / 3 – 4 dicembre 2022

39° Congresso Nazionale SIMG
Sessioni Live Virtuali, 19 – 22 novembre 2022

Comprehensive genomic profiling nella pratica clinica: l’esperienza con un test di profilazione ampia su tessuto e biopsia liquida di IEO
ed INT.

I mercoledì dell’oncologia
Webinar, 23 novembre 2022

Melanoma e Tumori Cutanei tra Stato dell’Arte ed Innovazione
Webinar Live, 24 novembre 2022

Immunotherapy Bridge
Napoli, 30 novembre – 1 dicembre 2022



Questi e altri appuntamenti si possono consultare sul sito AIOM: www.aiom.it


© 2020 Editore: 
Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 388 8896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867

Per contattare la redazione e commentare le notizie clicca qui
Per consultare i numeri arretrati della newsletter clicca qui

Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy


“Si ringrazia Pierre Fabre Pharma s.r.l. per il supporto incondizionato”